ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Effects of Extended-Release Liposomal Bupivacaine on Postoperative Mechanical and Thermal Hypersensitivity in C57BL/6 Mice (Mus musculus).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic analgesics, such as opioids and nonsteroidal anti-inflammatory drugs, may be contraindicated in certain studies due to their mechanisms of action and risk for systemic effects. Local anesthetics (LAs) are therefore crucial in managing postoperative pain, potentially decreasing the need for systemic analgesics. However, the utility of standard formulation LAs is limited by their short duration. This study evaluated the use of a commercially available extended-release (XR) liposomal bupivacaine (LB) in a mouse paw incisional model. Our goal was to assess whether LB attenuates postoperative mechanical hypersensitivity (MH) and thermal hypersensitivity (TH). Adult female and male C57BL/6NCrl mice were randomly assigned to one of 3 groups: (1) 5 mg/kg SC meloxicam plus 3.25 mg/kg SC XR-buprenorphine (MELOX/XR-BUP); (2) 2 mg/kg intraincisional standard bupivacaine (SB); or (3) 6 mg/kg intraincisional LB. MH and TH were assessed on days -1 (baseline), 0 (2 hours postoperatively), 1, 2, 3, and 4 using von Frey and Hargreaves testing, respectively. Hind paw incisional surgery was performed on day 0. Both the MELOX/XR-BUP and SB groups demonstrated significant attenuation of MH on all postoperative days compared with baseline, while the LB group showed significant attenuation of MH on days 1-4. In the MELOX/XR-BUP group, there was a significant reduction in TH on days 1-3. In both the SB and LB groups, there was no significant reduction in TH across all postoperative days. Together, these data suggest that a single 6-mg/kg intraincisional dose of LB in C57BL/6NCrl mice does not attenuate TH over a 4-day postoperative period but does attenuate MH on postoperative days 1-4 in our incisional model. In comparing the treatments, we conclude that the relative ability of LB to attenuate postoperative MH and TH was inferior to that of MELOX/XR-BUP and comparable to that of SB in a mouse paw incisional model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.